76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
C Cellectar Biosciences Inc
C
Open
7.25 -20.85
Overview
Share price change
24h
Min
7.28
Max
9.2
Employees | 11 |
|---|
Recommendations | Buy |
|---|---|
12 Months Forecast | -62.22% downside |
Market Cap | 13M |
|---|---|
Previous open | 28.1 |
Previous close | 7.25 |
Cellectar Biosciences Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Cellectar Biosciences Inc Forecast
Price Target
By TipRanks
-62.22% downside
12 Months Forecast
Average 3 USD -62.22%
High 3 USD
Low 3 USD
Based on 2 Wall Street analysts offering 12 month price targets forCellectar Biosciences Inc - Dist in the last 3 months.
Financials
$
About Cellectar Biosciences Inc
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
